Skip to main content
New Republic No Vaccine

No Vaccine in Sight

As the world shifts its focus from containment to a cure, it’s become urgent to face up to the dangers of our reliance on pharmaceutical and biotech industries built to serve Wall Street and shareholder value over human needs and public health. The case for removing patent-barriers and expanding government control over drug research and development was already strong and gaining traction before the Covid-19 pandemic. The events of recent months, says a growing alliance of public health experts and industry reform advocates, have further exposed the faults of the current model and bolstered the case for alternatives. “Under the patent-model that drives the behavior and priorities of the drug industry, companies have no reason to focus resources on a potential pandemic-level virus like Ebola and coronavirus, because the chances of it being used within the term of a patent is too low,” said Rohit Malpani, the former policy director for the Médecins Sans Frontières Access Campaign who has advised Oxfam. “It’s never been clearer that something has to change.”


A public option in pharma wouldn’t require starting from scratch. A ready-made foundation exists in the Department of Health and Human Services and the NIH system, already the world’s biggest investor in biomedical research. HHS is the natural home for a new directing body with authority, stature, and funding on par with the wartime OSRD, argues Dana Brown, director of the Next System Project at the Democracy Collaborative, a think tank. A 2019 report written by Brown, Medicine for All: The Case for a Public Option in the Pharmaceutical Industry, provides a blueprint for how a national pharmaceutical institute positioned inside NIH could coordinate with federal, state, and local public entities, including university and federal labs, Department of Veterans Affairs supply depots, and Postal Service offices. “The power is there, as is a good bit of the infrastructure, to build a public pharma sector that reprioritizes R&D and eliminates issues of cost-related access,” said Brown.


Read the entire article at The New Republic.

Publication date: 2020-05-11
Parent publication: New Republic
Publication URL: https://newrepublic.com/article/157594/no-coronavirus-vaccine-big-pharma-drug-patent-system

More related work

Default Image

The Democracy Collaborative and The Democracy Collaborative Workers' Union agree to fair severance package for laid-off staff

TDC and union members have agreed to a package of protections that goes well beyond the baseline severance provisions for layoffs agreed to in TDC’s union contract.

read more
Default Image

HAN Anchoring Resilience: Aligning supply chains and impact purchasing for community health summit

The Healthcare Anchor Network (HAN) convened the “Anchoring Resilience: Aligning Supply Chains and Impact Purchasing for Community Health” summit to spark collaboration in the healthcare sector around onshoring and localizing production of PPE and other supplies, with an emphasis on equity, sustainability, and supply chain resilience.

read more
Default Image

Reimagining Personal Protective Equipment (PPE) Supply Chains

The Democracy Collaborative prepared a report, created for the Healthcare Anchor Network, which details the current status of the supply chain of PPE, the market shifts caused by COVID-19, and the potential solutions to ensure capacity within US health systems for the future.

read more